Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04014387 · ClinicalTrials.gov registry record · Phase 4
Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT04014387 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 40 participants.
The verdict
NCT04014387, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
Prior research has identified profound sleep disruption in individuals with PSP. Not only were these individuals sleeping relatively short periods at night, they were also not recuperating lost sleep during the day. Research also showed the relative preservation of a series of nuclei key in regulating wake and arousal. Investigators believe that therapeutically targeting wake promoting centers with a specific medication will improve sleep quality and overall well-being in PSP. To study this, investigators will be doing a double blind, within subject, remote clinical trial with 3 conditions: suvorexant- which targets a wake promoting system, zolpidem- a standard hypnotic that engages sleep promoting systems, versus placebo. Each condition will last 1 week and will be separated by a 1 week washout period on no sleep medications. Investigators will measure sleep patterns and daytime symptoms to determine if suvorexant, zolpidem, or both medications are safe and effective for treating sleep disturbances and improving overall well-being in PSP.
Interventions
- DRUG Placebo oral capsule
- DRUG Suvorexant
- DRUG Zolpidem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-06-02 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04014387
The ClinicalTrials.gov registry entry for NCT04014387 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral capsule is the first listed.
NCT04014387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04014387 about?
NCT04014387 is a clinical study titled "Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)". Prior research has identified profound sleep disruption in individuals with PSP. Not only were these individuals sleeping relatively short periods at night, they were also not recuperating lost sleep during the day. Research also showed the relative preservation of a series of nuclei key in regulati...
What is the current status of trial NCT04014387?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2019-06-02. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT04014387?
The interventions under investigation include: Placebo oral capsule (DRUG), Suvorexant (DRUG), Zolpidem (DRUG).
Who is sponsoring clinical trial NCT04014387?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.